Get started
Author

Yasmine Iddir

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023 · Elizabeth R. Tucker, Irene Jiménez, et al. · Clinical Cancer Research · 34
PDF
The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples
2021 · Ruben Van Paemel, Charlotte Vandeputte, et al. · European Journal of Cancer · 29
PDF
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma
2023 · Nathalie S.M. Lak, Lieke M.J. van Zogchel, et al. · JCO Precision Oncology · 25
PDF
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study
2022 · Olivia Ruhen, Nathalie S.M. Lak, et al. · JCO Precision Oncology · 24
PDF
Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK -Targeted Therapy
2024 · Charles Bobin, Yasmine Iddir, et al. · Clinical Cancer Research · 15
Cell-Free DNA Extracted from CSF for the Molecular Diagnosis of Pediatric Embryonal Brain Tumors
2023 · Mathieu Chicard, Yasmine Iddir, et al. · Cancers · 12
PDF
A SPRY1 domain cardiac ryanodine receptor variant associated with short-coupled torsade de pointes
2021 · Zahia Touat-Hamici, Malorie Blancard, et al. · Scientific Reports · 12
PDF
Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology
2026 · Marlinde C. Schoonbeek, Pierre Gestraud, et al. · npj Precision Oncology · 6
PDF
Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models
2023 · Aniello Federico, Apurva Gopisetty, et al. · Cancer Research · 5
Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial
2019 · Pablo Berlanga, Gudrun Schleiermacher, et al. · Cancer Research · 5
The ITCC-P4 PDX platform of pediatric cancers for preclinical testing
2026 · Aniello Federico, Apurva Gopisetty, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughputin vivo testing
2022 · Marcel Kool, Aniello Federico, et al. · Neuro-Oncology · 2
Data from The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
2023 · Pablo Berlanga, Gaelle Pierron, et al. · 1
Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing
2023 · Apurva Gopisetty, Aniello Federico, et al. · Cancer Research · 1
Data from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S3 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure 1 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 5 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Methods from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S2 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Table 4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S6 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S7 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Supplementary Figure S4 from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers
2026 · Aniello Federico, Apurva Gopisetty, et al.
Works count: 96
Citation count: 172
H-index: 7
I10-index: 7
Year
Topic
Type